{"result": {"id": "8dcdaf93-34e5-421b-88bf-8d8294fbc740", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>中华内分泌代谢杂志<|>ORGANIZATION<|>Chinese Journal of Endocrinology and Metabolism, a medical journal publishing research on endocrine and metabolic diseases)\n##\n(\"entity\"<|>Ann Intern Med<|>ORGANIZATION<|>Annals of Internal Medicine, a peer-reviewed medical journal)\n##\n(\"entity\"<|>BMJ<|>ORGANIZATION<|>British Medical Journal, a peer-reviewed medical journal)\n##\n(\"entity\"<|>JHypertension<|>ORGANIZATION<|>Journal of Hypertension, a peer-reviewed medical journal)\n##\n(\"entity\"<|>Hypertension<|>ORGANIZATION<|>A peer-reviewed journal focusing on hypertension research)\n##\n(\"entity\"<|>N EnglJMed<|>ORGANIZATION<|>The New England Journal of Medicine, a prestigious medical journal)\n##\n(\"entity\"<|>Circulation<|>ORGANIZATION<|>A journal of the American Heart Association publishing cardiovascular research)\n##\n(\"entity\"<|>Lancet<|>ORGANIZATION<|>The Lancet, a weekly peer-reviewed general medical journal)\n##\n(\"relationship\"<|>中华内分泌代谢杂志<|>宗文漪<|>The journal published research by Zong WenYi and colleagues<|>3)\n##\n(\"relationship\"<|>Ann Intern Med<|>Elmer PJ<|>The journal published research by Elmer PJ and colleagues<|>3)\n##\n(\"relationship\"<|>BMJ<|>Cook NR<|>The journal published research by Cook NR and colleagues<|>3)\n##\n(\"relationship\"<|>JHypertension<|>Dickinson HO<|>The journal published research by Dickinson HO and colleagues<|>3)\n##\n(\"relationship\"<|>Hypertension<|>He J<|>The journal published research by He J and colleagues<|>3)\n##\n(\"relationship\"<|>N EnglJMed<|>Beckett NS<|>The journal published research by Beckett NS and colleagues<|>3)\n##\n(\"relationship\"<|>N EnglJMed<|>Parving HH<|>The journal published research by Parving HH and colleagues<|>3)\n##\n(\"relationship\"<|>N EnglJMed<|>Lewis EJ<|>The journal published research by Lewis EJ and colleagues<|>3)\n##\n(\"relationship\"<|>Circulation<|>Okin PM<|>The journal published research by Okin PM and colleagues<|>3)\n##\n(\"relationship\"<|>Lancet<|>Brown MJ<|>The journal published research by Brown MJ and colleagues<|>3)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752166515, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 581, "prompt_tokens": 5899, "total_tokens": 6480, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 5824}, "prompt_cache_hit_tokens": 5824, "prompt_cache_miss_tokens": 75}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 委员会. 中国高血压防治指南 2010[J]. 中华心血管病杂志，2011,39(7):579-616.DOI: 10.3760/cma.j.issn.0253-3758.2011.07.002.\n[2] 《中国高血压防治指南》修订委员会.2018年中国高血压防 治指南修订版[M].北京：中国医药科技出版社，2018.\n[3]     Elmer    PJ,Obarzanek    E,Vollmer    WM,et    al.Effects    of comprehensive lifestyle modification on diet,weight,physical fitness,and  blood  pressure   control:18-month  results   of  a randomized trial[J].Ann Intern Med,2006,144(7):485-495.\n[4]     Cook  NR,Cutler  JA,Obarzanek  E,et  al.Long term  effects  of\n\n\ndietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP)[J].BMJ,2007,334(7599):885-888.DOI:10.1136/\nbmj.39147.604896.55.\n[5]     Dickinson     HO,Mason     JM,Nicolson     DJ,et     al.Lifestyle  interventions  to  reduce  raised  blood  pressure:a   systematic review of randomized controlled trials[J].JHypertension,2006, 24(2):215-233.DOI:10.1097/01.hjh.0000199800.72563.26.\n[6]     He J,Whelton PK,Appel LJ,et al.Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension [J].Hypertension,2000,35(2):544-549.\n[7]     Beckett     NS,Peters    R,Fletcher     AE,et    al.Treatment     of hypertension in patients 80 years ofage orolder[J].N EnglJMed, 2008,358(18):1887-1898.DOI:10.1056/NEJMoa0801369.\n[8]     Okin  PM,Oikarinen  L,Viitasalo  M,et  al.Prognostic  value  of changes  in  the  electrocardiographic  strain  pattern  during antihypertensive   treatment:the   Losartan   Intervention   for End-Point   Reduction    in    Hypertension   Study   (LIFE)[J]. Circulation,2009,119(14):1883-1891.DOI:10.1161                  / CIRCULATIONAHA.108.812313.\n[9]     Parving    HH,Lehnert    H,Brochner-Mortensen    J,et    al.The effect   of   irbesartan    on    the    development    of   diabetic  nephropathy in patients with type 2 diabetes[J].N EnglJ Med, 2001,345(12):870-878.DOI:10.1056/NEJMoa011489.\n[10]  宗文漪，杨文英，向红丁，等.厄贝沙坦治疗2型糖尿病伴 白蛋白尿患者有效性和安全性——多中心随机双盲对照 研 究[J].  中华内分泌代谢杂志，2008,24(1):55-58.DOI:\n10.3321/j.issn.1000-6699.2008.01.016.\n[11]     Lewis    EJ,Hunsicker   LG,Clarke    WR,et   al.Renoprotective effect  of  the  angiotensin-receptor  antagonist  irbesartan  in patients with nephropathy due to type 2 diabetes[J].N Engl J Med,2001,345(12):851-860.DOI:10.1056/NEJMoa011303.\n[12]     Liu  L,Zhang  Y,Liu  G,et al.The Felodipine Event Reduction (FEVER)Study:a  randomized  long-term  placebo-controlled  trial in Chinese hypertensive patients[J].J Hypertens,2005,23 (12):2157-2172.\n[13]  中华医学会心血管病学分会高血压学组.清晨血压临床管 理的中国专家指导建议[J]. 中华心血管病杂志，2014,42(9): 721-725.DOI:10.3760/cma.j.issn.0253-3758.2014.09.003\n[14]     Brown    MJ,Palmer   CR,Castaigne    A,et    al.Morbidity   and mortality  in  patients  randomised  to  double-blind  treatment  with a long-acting calcium-channel blocker or diuretic in the  International Nifedipine GITS study:Intervention as a Goal in Hypertension      Treatment      (INSIGHT)[J].Lancet,2000,356 (9227):366\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>《中国高血压防治指南》修订委员会<|>ORGANIZATION<|>Committee responsible for revising the Chinese hypertension prevention and treatment guidelines)\n##\n(\"entity\"<|>中华心血管病杂志<|>ORGANIZATION<|>Chinese Journal of Cardiology, a medical journal publishing research on cardiovascular diseases)\n##\n(\"entity\"<|>中国医药科技出版社<|>ORGANIZATION<|>China Medical Science and Technology Press, a publisher of medical literature)\n##\n(\"entity\"<|>中华医学会心血管病学分会高血压学组<|>ORGANIZATION<|>Hypertension Group of the Chinese Society of Cardiology, part of the Chinese Medical Association)\n##\n(\"entity\"<|>Elmer PJ<|>PERSON<|>Researcher involved in studies on lifestyle modifications and blood pressure control)\n##\n(\"entity\"<|>Obarzanek E<|>PERSON<|>Researcher involved in studies on dietary sodium reduction and hypertension prevention)\n##\n(\"entity\"<|>Vollmer WM<|>PERSON<|>Researcher involved in studies on lifestyle modifications and blood pressure control)\n##\n(\"entity\"<|>Cook NR<|>PERSON<|>Researcher involved in long-term studies on dietary sodium reduction and cardiovascular disease outcomes)\n##\n(\"entity\"<|>Cutler JA<|>PERSON<|>Researcher involved in long-term studies on dietary sodium reduction and cardiovascular disease outcomes)\n##\n(\"entity\"<|>Dickinson HO<|>PERSON<|>Researcher involved in systematic reviews of lifestyle interventions to reduce blood pressure)\n##\n(\"entity\"<|>Mason JM<|>PERSON<|>Researcher involved in systematic reviews of lifestyle interventions to reduce blood pressure)\n##\n(\"entity\"<|>Nicolson DJ<|>PERSON<|>Researcher involved in systematic reviews of lifestyle interventions to reduce blood pressure)\n##\n(\"entity\"<|>He J<|>PERSON<|>Researcher involved in studies on long-term effects of weight loss and dietary sodium reduction on hypertension incidence)\n##\n(\"entity\"<|>Whelton PK<|>PERSON<|>Researcher involved in studies on long-term effects of weight loss and dietary sodium reduction on hypertension incidence)\n##\n(\"entity\"<|>Appel LJ<|>PERSON<|>Researcher involved in studies on long-term effects of weight loss and dietary sodium reduction on hypertension incidence)\n##\n(\"entity\"<|>Beckett NS<|>PERSON<|>Researcher involved in studies on hypertension treatment in elderly patients)\n##\n(\"entity\"<|>Peters R<|>PERSON<|>Researcher involved in studies on hypertension treatment in elderly patients)\n##\n(\"entity\"<|>Fletcher AE<|>PERSON<|>Researcher involved in studies on hypertension treatment in elderly patients)\n##\n(\"entity\"<|>Okin PM<|>PERSON<|>Researcher involved in studies on the prognostic value of electrocardiographic strain patterns during antihypertensive treatment)\n##\n(\"entity\"<|>Oikarinen L<|>PERSON<|>Researcher involved in studies on the prognostic value of electrocardiographic strain patterns during antihypertensive treatment)\n##\n(\"entity\"<|>Viitasalo M<|>PERSON<|>Researcher involved in studies on the prognostic value of electrocardiographic strain patterns during antihypertensive treatment)\n##\n(\"entity\"<|>Parving HH<|>PERSON<|>Researcher involved in studies on the effects of irbesartan on diabetic nephropathy in patients with type 2 diabetes)\n##\n(\"entity\"<|>Lehnert H<|>PERSON<|>Researcher involved in studies on the effects of irbesartan on diabetic nephropathy in patients with type 2 diabetes)\n##\n(\"entity\"<|>Brochner-Mortensen J<|>PERSON<|>Researcher involved in studies on the effects of irbesartan on diabetic nephropathy in patients with type 2 diabetes)\n##\n(\"entity\"<|>宗文漪<|>PERSON<|>Researcher involved in multicenter randomized double-blind controlled studies on irbesartan for type 2 diabetes patients with albuminuria)\n##\n(\"entity\"<|>杨文英<|>PERSON<|>Researcher involved in multicenter randomized double-blind controlled studies on irbesartan for type 2 diabetes patients with albuminuria)\n##\n(\"entity\"<|>向红丁<|>PERSON<|>Researcher involved in multicenter randomized double-blind controlled studies on irbesartan for type 2 diabetes patients with albuminuria)\n##\n(\"entity\"<|>Lewis EJ<|>PERSON<|>Researcher involved in studies on the renoprotective effects of irbesartan in patients with nephropathy due to type 2 diabetes)\n##\n(\"entity\"<|>Hunsicker LG<|>PERSON<|>Researcher involved in studies on the renoprotective effects of irbesartan in patients with nephropathy due to type 2 diabetes)\n##\n(\"entity\"<|>Clarke WR<|>PERSON<|>Researcher involved in studies on the renoprotective effects of irbesartan in patients with nephropathy due to type 2 diabetes)\n##\n(\"entity\"<|>Liu L<|>PERSON<|>Researcher involved in the Felodipine Event Reduction (FEVER) Study)\n##\n(\"entity\"<|>Zhang Y<|>PERSON<|>Researcher involved in the Felodipine Event Reduction (FEVER) Study)\n##\n(\"entity\"<|>Liu G<|>PERSON<|>Researcher involved in the Felodipine Event Reduction (FEVER) Study)\n##\n(\"entity\"<|>Brown MJ<|>PERSON<|>Researcher involved in the International Nifedipine GITS study)\n##\n(\"entity\"<|>Palmer CR<|>PERSON<|>Researcher involved in the International Nifedipine GITS study)\n##\n(\"entity\"<|>Castaigne A<|>PERSON<|>Researcher involved in the International Nifedipine GITS study)\n##\n(\"entity\"<|>Trials of Hypertension Prevention (TOHP)<|>EVENT<|>A study on the long-term effects of dietary sodium reduction on cardiovascular disease outcomes)\n##\n(\"entity\"<|>Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE)<|>EVENT<|>A study on the prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment)\n##\n(\"entity\"<|>Felodipine Event Reduction (FEVER) Study<|>EVENT<|>A randomized long-term placebo-controlled trial in Chinese hypertensive patients)\n##\n(\"entity\"<|>International Nifedipine GITS study<|>EVENT<|>A study comparing the effects of a long-acting calcium-channel blocker or diuretic in hypertension treatment)\n##\n(\"relationship\"<|>《中国高血压防治指南》修订委员会<|>中华心血管病杂志<|>The committee published guidelines in the Chinese Journal of Cardiology<|>5)\n##\n(\"relationship\"<|>《中国高血压防治指南》修订委员会<|>中国医药科技出版社<|>The committee published revised guidelines with China Medical Science and Technology Press<|>5)\n##\n(\"relationship\"<|>中华医学会心血管病学分会高血压学组<|>中华心血管病杂志<|>The group published expert recommendations in the Chinese Journal of Cardiology<|>5)\n##\n(\"relationship\"<|>Elmer PJ<|>Obarzanek E<|>Co-authors on a study about lifestyle modifications and blood pressure control<|>3)\n##\n(\"relationship\"<|>Elmer PJ<|>Vollmer WM<|>Co-authors on a study about lifestyle modifications and blood pressure control<|>3)\n##\n(\"relationship\"<|>Obarzanek E<|>Vollmer WM<|>Co-authors on a study about lifestyle modifications and blood pressure control<|>3)\n##\n(\"relationship\"<|>Cook NR<|>Cutler JA<|>Co-authors on a study about dietary sodium reduction and cardiovascular disease outcomes<|>3)\n##\n(\"relationship\"<|>Cook NR<|>Obarzanek E<|>Co-authors on a study about dietary sodium reduction and cardiovascular disease outcomes<|>3)\n##\n(\"relationship\"<|>Cutler JA<|>Obarzanek E<|>Co-authors on a study about dietary sodium reduction and cardiovascular disease outcomes<|>3)\n##\n(\"relationship\"<|>Dickinson HO<|>Mason JM<|>Co-authors on a systematic review of lifestyle interventions to reduce blood pressure<|>3)\n##\n(\"relationship\"<|>Dickinson HO<|>Nicolson DJ<|>Co-authors on a systematic review of lifestyle interventions to reduce blood pressure<|>3)\n##\n(\"relationship\"<|>Mason JM<|>Nicolson DJ<|>Co-authors on a systematic review of lifestyle interventions to reduce blood pressure<|>3)\n##\n(\"relationship\"<|>He J<|>Whelton PK<|>Co-authors on a study about long-term effects of weight loss and dietary sodium reduction on hypertension incidence<|>3)\n##\n(\"relationship\"<|>He J<|>Appel LJ<|>Co-authors on a study about long-term effects of weight loss and dietary sodium reduction on hypertension incidence<|>3)\n##\n(\"relationship\"<|>Whelton PK<|>Appel LJ<|>Co-authors on a study about long-term effects of weight loss and dietary sodium reduction on hypertension incidence<|>3)\n##\n(\"relationship\"<|>Beckett NS<|>Peters R<|>Co-authors on a study about hypertension treatment in elderly patients<|>3)\n##\n(\"relationship\"<|>Beckett NS<|>Fletcher AE<|>Co-authors on a study about hypertension treatment in elderly patients<|>3)\n##\n(\"relationship\"<|>Peters R<|>Fletcher AE<|>Co-authors on a study about hypertension treatment in elderly patients<|>3)\n##\n(\"relationship\"<|>Okin PM<|>Oikarinen L<|>Co-authors on a study about the prognostic value of electrocardiographic strain patterns during antihypertensive treatment<|>3)\n##\n(\"relationship\"<|>Okin PM<|>Viitasalo M<|>Co-authors on a study about the prognostic value of electrocardiographic strain patterns during antihypertensive treatment<|>3)\n##\n(\"relationship\"<|>Oikarinen L<|>Viitasalo M<|>Co-authors on a study about the prognostic value of electrocardiographic strain patterns during antihypertensive treatment<|>3)\n##\n(\"relationship\"<|>Parving HH<|>Lehnert H<|>Co-authors on a study about the effects of irbesartan on diabetic nephropathy in patients with type 2 diabetes<|>3)\n##\n(\"relationship\"<|>Parving HH<|>Brochner-Mortensen J<|>Co-authors on a study about the effects of irbesartan on diabetic nephropathy in patients with type 2 diabetes<|>3)\n##\n(\"relationship\"<|>Lehnert H<|>Brochner-Mortensen J<|>Co-authors on a study about the effects of irbesartan on diabetic nephropathy in patients with type 2 diabetes<|>3)\n##\n(\"relationship\"<|>宗文漪<|>杨文英<|>Co-authors on a multicenter randomized double-blind controlled study on irbesartan for type 2 diabetes patients with albuminuria<|>3)\n##\n(\"relationship\"<|>宗文漪<|>向红丁<|>Co-authors on a multicenter randomized double-blind controlled study on irbesartan for type 2 diabetes patients with albuminuria<|>3)\n##\n(\"relationship\"<|>杨文英<|>向红丁<|>Co-authors on a multicenter randomized double-blind controlled study on irbesartan for type 2 diabetes patients with albuminuria<|>3)\n##\n(\"relationship\"<|>Lewis EJ<|>Hunsicker LG<|>Co-authors on a study about the renoprotective effects of irbesartan in patients with nephropathy due to type 2 diabetes<|>3)\n##\n(\"relationship\"<|>Lewis EJ<|>Clarke WR<|>Co-authors on a study about the renoprotective effects of irbesartan in patients with nephropathy due to type 2 diabetes<|>3)\n##\n(\"relationship\"<|>Hunsicker LG<|>Clarke WR<|>Co-authors on a study about the renoprotective effects of irbesartan in patients with nephropathy due to type 2 diabetes<|>3)\n##\n(\"relationship\"<|>Liu L<|>Zhang Y<|>Co-authors on the Felodipine Event Reduction (FEVER) Study<|>3)\n##\n(\"relationship\"<|>Liu L<|>Liu G<|>Co-authors on the Felodipine Event Reduction (FEVER) Study<|>3)\n##\n(\"relationship\"<|>Zhang Y<|>Liu G<|>Co-authors on the Felodipine Event Reduction (FEVER) Study<|>3)\n##\n(\"relationship\"<|>Brown MJ<|>Palmer CR<|>Co-authors on the International Nifedipine GITS study<|>3)\n##\n(\"relationship\"<|>Brown MJ<|>Castaigne A<|>Co-authors on the International Nifedipine GITS study<|>3)\n##\n(\"relationship\"<|>Palmer CR<|>Castaigne A<|>Co-authors on the International Nifedipine GITS study<|>3)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_8474c049983edd61d5f80e672966a37e59846a7539a1fa4358e1fe41ec202637_v2"}